Randomized controlled trial of a gastrin receptor blocker in Barrett’s esophagus


Randomized, placebo-controlled trial of netazepide (YF476), a gastrin receptor antagonist, in Barrett’s esophagus

The purpose of this study is to determine whether the drug netazepide may potentially be able to lower the risk of esophageal cancer in patients with Barrett’s esophagus.

Are you Eligible? (Inclusion Criteria)

  • History of Barrett’s esophagus
  • No previous endoscopic treatment for Barrett’s esophagus
  • No precancerous changes (dysplasia) or esophageal cancer associated with the Barrett’s esophagus
  • Use of proton pump inhibitors (PPIs; examples include Prilosec (omeprazole) and Nexium) at least once daily for the past year

Specialty Area(s)

Trial Location

Columbia University Medical Center
United States